| Cell Adhesion Molecules Research | Lifetime | 462 | TW 2 | 98.54 |
| Chemokine receptors and signaling | Lifetime | 117 | TW 1 | 97.80 |
| Bone health and treatments | Lifetime | 300 | TW 1 | 98.51 |
| NF-κB Signaling Pathways | Lifetime | 199 | TW 3 | 97.88 |
| Protease and Inhibitor Mechanisms | Lifetime | 313 | TW 2 | 97.86 |
| Bone Metabolism and Diseases | Lifetime | 244 | TW 1 | 98.26 |
| Biomarkers in Disease Mechanisms | Lifetime | 72 | TW 1 | 96.51 |
| Connective Tissue Growth Factor Research | Lifetime | 38 | TW 1 | 97.66 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 493 | TW 3 | 97.94 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 457 | TW 3 | 97.57 |
| Inflammatory mediators and NSAID effects | Lifetime | 615 | TW 2 | 96.70 |
| TGF-β signaling in diseases | Lifetime | 252 | TW 1 | 96.21 |
| Angiogenesis and VEGF in Cancer | Lifetime | 839 | TW 11 | 95.55 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 37 | TW 1 | 95.01 |
| Chemokine receptors and signaling | 2021-2025 | 29 | TW 2 | 90.56 |
| Cell Adhesion Molecules Research | 2021-2025 | 93 | TW 1 | 90.22 |
| Osteoarthritis Treatment and Mechanisms | 2021-2025 | 263 | TW 2 | 94.37 |
| Bone Metabolism and Diseases | 2021-2025 | 132 | TW 1 | 90.59 |
| Inflammatory mediators and NSAID effects | 2021-2025 | 153 | TW 2 | 85.35 |
| Sarcoma Diagnosis and Treatment | 2021-2025 | 891 | TW 4 | 87.35 |
| Rheumatoid Arthritis Research and Therapies | 2021-2025 | 852 | TW 5 | 88.72 |
| Cancer-related gene regulation | 2021-2025 | 701 | TW 2 | 80.67 |
| Circadian rhythm and melatonin | 2021-2025 | 654 | TW 2 | 84.62 |
| Adipokines, Inflammation, and Metabolic Diseases | 2021-2025 | 724 | TW 6 | 79.41 |
| Angiogenesis and VEGF in Cancer | 2021-2025 | 246 | TW 7 | 77.80 |
| NF-κB Signaling Pathways | 2021-2025 | 121 | TW 6 | 72.87 |
| Bone health and treatments | 2021-2025 | 809 | TW 10 | 74.25 |
| Estrogen and related hormone effects | 2021-2025 | 762 | TW 2 | 73.83 |
| Fibroblast Growth Factor Research | 2021-2025 | 379 | TW 1 | 72.96 |
| Protease and Inhibitor Mechanisms | 2021-2025 | 365 | TW 6 | 73.51 |
| Connective Tissue Growth Factor Research | 2021-2025 | 55 | TW 2 | 73.51 |
| Medicinal Plant Pharmacodynamics Research | 2021-2025 | 79 | TW 2 | 66.37 |
| Apelin-related biomedical research | 2021-2025 | 249 | TW 2 | 65.20 |
| Galectins and Cancer Biology | 2021-2025 | 990 | TW 21 | 63.56 |
| Signaling Pathways in Disease | 2021-2025 | 507 | TW 6 | 60.10 |
| Lipid metabolism and disorders | 2021-2025 | 911 | TW 9 | 60.35 |
| Bone and Dental Protein Studies | 2021-2025 | 675 | TW 3 | 54.08 |
| Cardiovascular, Neuropeptides, and Oxidative Stress Research | 2021-2025 | 488 | TW 17 | 49.39 |
| Biomarkers in Disease Mechanisms | 2021-2025 | 600 | TW 10 | 50.16 |
